Maze Therapeutics, Inc.(MAZE)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Maze Therapeutics, Inc. (MAZE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MAZE at 10.3/100 on a 32-signal composite quality model, placing it at rank #2,910 of 2,960 stocks — the bottom half of the AI-ranked universe. MAZE scores in the top quartile across institutional flow (93.3). Areas of concern include revenue growth (1.0) and free cash flow (2.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Maze Therapeutics, Inc. reports net income of $-44.7M, free cash flow of $-15.2M. Top institutional holders of MAZE by reported 13-F value include Frazier Life Sciences Management, L.P., TRV GP IV, ARCH Venture Management, based on the most recent SEC filings. MAZE trades on the Nasdaq exchange and files with the SEC under CIK 1842295. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MAZE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Maze Therapeutics, Inc. directly from SEC EDGAR.